SG
Publicaties op Oncologisch.com
Adjuvant nivolumab versus placebo for high-risk muscle-invasive urothelial carcinoma: 5-year efficacy and ctDNA resul...
Enfortumab vedotin plus pembrolizumab in untreated locally gevorderd or metastatic urothelial carcinoma: 2.5-year med...
Vroeg mammacarcinoom: ESMO 2024 richtlijn
Pan-Aziatische ESMO-richtlijn voor vroeg mammacarcinoom